Deng Xiao-Long, Ma Rui, Zhu Hong-Xia, Zhu Jun
aDepartments of Endocrinology, the First Affiliated Hospital of Xinjiang Medical University bDepartment of Endocrinology, The Fifth Affiliated Hospital of XinJiang Medical University, Urumqi, Xinjiang, China.
Eur J Gastroenterol Hepatol. 2017 Mar;29(3):297-301. doi: 10.1097/MEG.0000000000000780.
This study aimed to evaluate the efficacy and safety of sitagliptin for treating Chinese patients with type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD).
In total, 72 Chinese T2DM patients with NAFLD were divided randomly into two groups of 36 patients each group. All 72 patients were assigned to receive either sitagliptin or diet and exercise for 52 weeks between January 2013 and December 2015. The outcomes' measurements included serum levels of hemoglobin A1c, fasting plasma glucose, aspartate aminotransferase, and alanine aminotransferase.
Seventy patients completed the study. Sitagliptin showed greater efficacy than the diet and exercise in decreasing the hemoglobin A1c and fasting plasma glucose levels at weeks 13, 26, 39, and 52. In addition, no significant changes in the average aspartate aminotransferase and alanine aminotransferase levels were found during the 52-week follow-up in both the sitagliptin and the control groups.
The results of this study indicate that sitagliptin is an effective and safe treatment for patients with T2DM and NAFLD.
本研究旨在评估西他列汀治疗中国 2 型糖尿病（T2DM）合并非酒精性脂肪性肝病（NAFLD）患者的疗效和安全性。
总共 72 例中国 T2DM 合并 NAFLD 患者被随机分为两组，每组 36 例。在 2013 年 1 月至 2015 年 12 月期间，所有 72 例患者被分配接受西他列汀治疗或饮食及运动干预，为期 52 周。观察指标包括糖化血红蛋白、空腹血糖、天冬氨酸转氨酶和丙氨酸转氨酶的血清水平。
70 例患者完成了研究。在第 13、26、39 和 52 周时，西他列汀在降低糖化血红蛋白和空腹血糖水平方面显示出比饮食及运动干预更显著的疗效。此外，在 52 周的随访期间，西他列汀组和对照组的平均天冬氨酸转氨酶和丙氨酸转氨酶水平均未发现显著变化。
本研究结果表明，西他列汀是治疗 T2DM 合并 NAFLD 患者的一种有效且安全的治疗方法。
Zotero 插件